[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Dugan et al., 2021 - Google Patents

Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets

Dugan et al., 2021

View HTML @Full View
Document ID
7325586989474160285
Author
Dugan H
Stamper C
Li L
Changrob S
Asby N
Halfmann P
Zheng N
Huang M
Shaw D
Cobb M
Erickson S
Guthmiller J
Stovicek O
Wang J
Winkler E
Madariaga M
Shanmugarajah K
Jansen M
Amanat F
Stewart I
Utset H
Huang J
Nelson C
Dai Y
Hall P
Jedrzejczak R
Joachimiak A
Krammer F
Diamond M
Fremont D
Kawaoka Y
Wilson P
Publication year
Publication venue
Immunity

External Links

Snippet

Dissecting the evolution of memory B cells (MBCs) against SARS-CoV-2 is critical for understanding antibody recall upon secondary exposure. Here, we used single-cell sequencing to profile SARS-CoV-2-reactive B cells in 38 COVID-19 patients. Using oligo …
Continue reading at www.cell.com (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses

Similar Documents

Publication Publication Date Title
Dugan et al. Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets
Smith et al. Immunogenicity of a DNA vaccine candidate for COVID-19
Dogan et al. SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus
Alsoussi et al. SARS-CoV-2 Omicron boosting induces de novo B cell response in humans
Bruel et al. Serum neutralization of SARS-CoV-2 Omicron sublineages BA. 1 and BA. 2 in patients receiving monoclonal antibodies
Rogers et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model
Lucas et al. Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity
Alsoussi et al. A potently neutralizing antibody protects mice against SARS-CoV-2 infection
Dugan et al. Preexisting immunity shapes distinct antibody landscapes after influenza virus infection and vaccination in humans
Horns et al. Memory B cell activation, broad anti-influenza antibodies, and bystander activation revealed by single-cell transcriptomics
Turner et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses
Sterlin et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2
Chen et al. Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals
Brewer et al. BNT162b2 vaccine induces divergent B cell responses to SARS-CoV-2 S1 and S2
Yang et al. Shared B cell memory to coronaviruses and other pathogens varies in human age groups and tissues
Pušnik et al. Memory B cells targeting SARS-CoV-2 spike protein and their dependence on CD4+ T cell help
Shrock et al. Germline-encoded amino acid–binding motifs drive immunodominant public antibody responses
Ekiert et al. A highly conserved neutralizing epitope on group 2 influenza A viruses
Klompus et al. Cross-reactive antibodies against human coronaviruses and the animal coronavirome suggest diagnostics for future zoonotic spillovers
Amanat et al. The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies and targets both the NTD and the RBD
Gao et al. The dichotomous and incomplete adaptive immunity in COVID-19 patients with different disease severity
Mader et al. Omicron’s binding to sotrovimab, casirivimab, imdevimab, CR3022, and sera from previously infected or vaccinated individuals
Natarajan et al. SARS-CoV-2 antibody signatures robustly predict diverse antiviral functions relevant for convalescent plasma therapy
Muik et al. Progressive loss of conserved spike protein neutralizing antibody sites in Omicron sublineages is balanced by preserved T cell immunity
Stamper et al. Distinct B cell subsets give rise to antigen-specific antibody responses against SARS-CoV-2